Age‐Related Risk Stratification in HPV ‐Positive Oropharyngeal Cancer: Implications for Treatment De‐Intensification
Head & Neck · 2026
DOI: 10.1002/hed.70167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, 2026. Verfasst von Chuanhao Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Dalian Medical University, Dalian, People's Republic of China. Hauptthemen laut MEDLINE: Oropharyngeal Neoplasms, Papillomavirus Infections. Die Arbeit nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Revitalizing Liaoning Talents Program-Medical Experts Project, Liaoning Provincial International Science and Technology Cooperation Project.
Abstract (Originalsprache)
Background
Although the AJCC eighth edition staging system incorporates HPV status, it remains insufficient to guide personalized treatment in HPV‐positive oropharyngeal cancer (OPC). This study aimed to identify the optimal age threshold and evaluate its association with overall survival (OS) to improve risk stratification and inform individualized treatment strategies.
Methods
Data were extracted from the SEER database (2018–2021), the University Health Network (UHN), University of Toronto, and the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (NCC). Only HPV‐positive OPC cases with complete survival records were included. The optimal age threshold was identified using restricted cubic spline modeling in combination with a recursive partitioning approach. Prognostic factors beyond HPV status and AJCC eighth edition stage were evaluated using multivariable Cox proportional hazards models. Recursive partitioning analysis (RPA) was used to construct a risk stratification model. The primary endpoint was OS.
Results
Of the 10 283 eligible patients (87.9% male; median age, 62 years), 2.7% had distant metastases at diagnosis. Restricted cubic spline analysis revealed that 62 years of age represents an important critical threshold. Multivariable Cox analysis revealed that patients younger than 62 years exhibited significantly improved OS (HR, 0.61; 95% CI, 0.54–0.70; p < 0.001). RPA stratified patients into five risk groups with distinct 2‐year OS: extremely low (96.8%), low (93.7%), intermediate (86.1%), high (74.6%), and extremely high risk (47.5%). Among patients classified in the extremely low‐risk group (T0‐2N0‐1M0 and younger than 62 years), no significant difference in OS was observed between those treated with radiotherapy alone and those treated with chemoradiotherapy. External validation in the UHN ( N = 843) and NCC ( N = 167) cohorts suggested that extremely low‐risk patients might be spared concurrent chemotherapy.
Conclusions
This study developed a risk stratification model for patients with p16‐positive OPC based on the AJCC eighth edition staging and age. Patients in the extremely low‐risk group may derive limited benefit from concurrent chemotherapy, suggesting that its omission could be considered in selected patients and may help guide the design of future de‐escalation trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Graduate School of Dalian Medical University, Dalian, People's Republic of China.
- Department of Medical Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian, People's Republic of China.
- The Key Laboratory of Biomarker High Throughput Screening and Target Translation of Breast and Gastrointestinal Tumor, Dalian University, Dalian, People's Republic of China.
- Department of Radiation Oncology, The First Hospital of Jilin University, Changchun, People's Republic of China.
- Department of Medical and Radiation Oncology, Affiliated Sanming Hospital, Fujian Medical University, Sanming, People's Republic of China.
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of…
ORCID-Profile: Chuanhao Zhang, Zhichao Cheng, Xin Jiang, Genghao Zhao, Yingming Sun, Shanshan Liang, Zhe Wang, Ruoyu Wang
Förderung
- National Natural Science Foundation of China
- Revitalizing Liaoning Talents Program-Medical Experts Project
- Liaoning Provincial International Science and Technology Cooperation Project
- Liaoning Provincial Science and Technology Plan-Joint Program-Key Technology Research Project
Zitieren
APA
Zhang, C., Cheng, Z., Jiang, X., Zhao, G., Zhu, Y., Hou, B., Sun, Y., Liang, S., Zhang, Y., Wang, Z., & Wang, R. (2026). Age‐Related Risk Stratification in HPV ‐Positive Oropharyngeal Cancer: Implications for Treatment De‐Intensification. Head & Neck. https://doi.org/10.1002/hed.70167
Vancouver
Zhang C, Cheng Z, Jiang X, Zhao G, Zhu Y, Hou B, et al. Age‐Related Risk Stratification in HPV ‐Positive Oropharyngeal Cancer: Implications for Treatment De‐Intensification. Head & Neck. 2026. doi:10.1002/hed.70167
BibTeX
@article{Zhang2026,
author = {Zhang, Chuanhao and Cheng, Zhichao and Jiang, Xin and Zhao, Genghao and Zhu, Yanmei and Hou, Bowen and Sun, Yingming and Liang, Shanshan and Zhang, Ye and Wang, Zhe and Wang, Ruoyu},
title = {Age‐Related Risk Stratification in HPV ‐Positive Oropharyngeal Cancer: Implications for Treatment De‐Intensification},
journal = {Head & Neck},
year = {2026},
doi = {10.1002/hed.70167}
}
EUVIMED